Saturday, May 4, 2024 5/4/2024

Implementing Universal Lynch Syndrome Screening across Multiple Healthcare Systems: Identifying Strategies to Facilitate and Maintain Programs in Different Organizational Contexts

Award Number: R01CA211723
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By Issue Date FY or Funding FY:

View Award Abstract

Project Summary/Abstract Lynch syndrome (LS) is the most common form of inherited colorectal cancer risk. People with Lynch syndrome are also at increased risk for endometrial, ovarian, gastric, small bowel, and renal cancers. Importantly, well-established clinical guidelines with strong evidence exist for cancer treatment, screening, and prevention in individuals with LS. Identification of individuals with LS is accomplished through a variety of techniques, including family and medical history evaluation, computational models, or tumor testing. The systematic screening of all colorectal tumors for LS was first recommended by the Evaluation of Genetic Application in Practice and Prevention (EGAPP) working group in 2009 and has been designated high priority by the National Academies of Science, Engineering, and Medicine working group and by the Blue Ribbon Panel. The potential public health impact to reduce cancer morbidity and mortality of this intervention supports this priority, as effective implementation of LS screening will help meet the goals of the Cancer Moonshot as well as demonstrate the promise of precision medicine. Currently, implementation of LS screening in healthcare systems remains suboptimal for a variety of reasons. LS screening involves the coordination of multiple departments and individuals across an organization, which is often difficult in large, complex, healthcare systems. Therefore, the overarching goal of this project is to utilize tools from implementation science to describe, explain, and compare decision making and other variations in LS screening implementation across multiple healthcare systems to create and evaluate in a real world setting an organizational toolkit to facilitate implementation of LS screening. Our specific aims are to (1) Describe variation in LS screening implementation across multiple healthcare systems; then (2) Explain practice variation and determine factors associated with optimal implementation; and (3) Determine the relative effectiveness, efficiency, and costs of different LS screening protocols by healthcare system; and finally to (4) Develop and test in a natural environment an organizational toolkit for LS screening. This toolkit will enable effective implementation of LS screening programs; ultimately preventing needless suffering of patients and their family members from preventable cancers, decreasing waste in healthcare system costs, and informing strategies to facilitate the promise of precision medicine.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$3,172 )
2024	2021	GEISINGER CLINIC	100 N ACADEMY AVE # MC4970	DANVILLE	PA	17822	MONTOUR	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	5	3/1/2024	NON-COMPETING CONTINUATION	-$3,172
														Subtotal = -$3,172

Issue Date FY: 2021 ( Subtotal = $637,674 )
2021	2021	GEISINGER CLINIC	100 N ACADEMY AVE	DANVILLE	PA	17822	MONTOUR	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	5	7/26/2021	NON-COMPETING CONTINUATION	$637,674
														Subtotal = $637,674

Issue Date FY: 2020 ( Subtotal = $780,902 )
2020	2020	GEISINGER CLINIC	100 N ACADEMY AVE	DANVILLE	PA	17822	MONTOUR	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	4	7/30/2020	NON-COMPETING CONTINUATION	$780,902
														Subtotal = $780,902

Issue Date FY: 2019 ( Subtotal = $812,239 )
2019	2019	GEISINGER CLINIC	100 N ACADEMY AVE	DANVILLE	PA	17822	MONTOUR	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	3	7/25/2019	NON-COMPETING CONTINUATION	$649,351
2019	2019	GEISINGER CLINIC	100 N ACADEMY AVE	DANVILLE	PA	17822	MONTOUR	USA	Trans-NIH Research Support	001	3	8/19/2019	SUPPLEMENT FOR EXPANSION	$162,888
														Subtotal = $812,239

Issue Date FY: 2018 ( Subtotal = $653,747 )
2018	2018	GEISINGER CLINIC	100 N ACADEMY AVE	DANVILLE	PA	17822	MONTOUR	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	2	7/27/2018	NON-COMPETING CONTINUATION	$653,747
														Subtotal = $653,747

Issue Date FY: 2017 ( Subtotal = $807,436 )
2017	2017	GEISINGER CLINIC	100 N ACADEMY AVE	DANVILLE	PA	17822	MONTOUR	USA	21st Century Cures Act - Beau Biden Cancer Moonshot	000	1	7/31/2017	NEW	$807,436
														Subtotal = $807,436

Grand Total All Awards = $3,688,827

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Implementing Universal Lynch Syndrome Screening across Multiple Healthcare Systems: Identifying Strategies to Facilitate and Maintain Programs in Different Organizational Contexts

Award Number: R01CA211723

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer